SCHEMBL3883083

SCHEMBL3883083

N#Cc1ccc(O)c(S(N)(=O)=O)c1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.47
CA1 P00915 6/20 0.47
CA9 Q16790 6/20 0.47
CA12 O43570 5/20 0.47
RAD51 Q06609 1/20 0.45
TRPV4 Q9HBA0 1/20 0.44
MAOA P21397 3/20 0.42
MAOB P27338 2/20 0.42
PTGES2 Q9H7Z7 5/20 0.42
LDHA P00338 1/20 0.40
CA3 P07451 1/20 0.40
CA6 P23280 1/20 0.40
CA14 Q9ULX7 1/20 0.40
STS P08842 1/20 0.39
CA4 P22748 1/20 0.39
KDM1A O60341 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3778124 0.81 CA1 (0.47) CA2CA1CA9CA12RAD51
SCHEMBL22867349 0.79 CA1 (0.46) CA2CA1CA9CA12RAD51
SCHEMBL6559198 0.79 PTGES2 (0.53) CA2CA1CA9CA12RAD51
SCHEMBL2778205 0.79 ACLY (0.49) CA2CA1CA9CA12RAD51
SCHEMBL31296510 0.79 ACLY (0.49) CA2CA1CA9CA12RAD51
SCHEMBL31727449 0.77 CA1 (0.47) CA2CA1CA9CA12RAD51
SCHEMBL3782276 0.77 CA1 (0.47) CA2CA1CA9CA12RAD51
SCHEMBL14925398 0.76 PDIA6 (0.47) CA2CA1CA9CA12RAD51
SCHEMBL20744421 0.76 PTGES2 (0.50) CA2CA1CA9CA12RAD51
SCHEMBL2775587 0.76 TRPV4 (0.46) CA2CA1CA9CA12RAD51

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1331221-B1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION KISSEI PHARMACEUTICAL (JP) 2009-01-14 EP claimed
CN-100439329-C 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing them and intermediates for their preparation KISSEI PHARMACEUTICAL (JP) 2008-12-03 CN claimed
US-7217832-B2 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-05-15 US claimed
US-20060205812-A1 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation KISSEI PHARMACEUTICAL CO., LTD. 2006-09-14 US claimed
US-20050014787-A1 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US claimed
EP-1443041-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP claimed
CN-1468215-A 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation ����ҩƷ��ҵ��ʽ���� 2004-01-14 CN claimed
EP-1331221-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION Kissei Pharmaceutical Co., Ltd. (JP) 2003-07-30 EP claimed
US-7589126-B2 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
US-7563822-B2 Agents for the prevention or treatment of renal diseases KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-07-21 US disclosed
EP-1331221-B1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION KISSEI PHARMACEUTICAL (JP) 2009-01-14 EP disclosed
CN-100439329-C 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing them and intermediates for their preparation KISSEI PHARMACEUTICAL (JP) 2008-12-03 CN disclosed
CN-100341496-C Agent for preventing or treating kidney disease KISSEI PHARMACEUTICAL (JP) 2007-10-10 CN disclosed
US-7217832-B2 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-05-15 US disclosed
US-20050014787-A1 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
US-20040242455-A1 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor KISSEI PAHRMACEUTICAL CO., LTD. (JP) 2004-12-02 US disclosed
EP-1443041-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed
EP-1415983-A1 5-AMIDINO-N-(2-AMINOPHENETHYL)-HYDROXYBENZENESULFONAMIDE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR Kissei Pharmaceutical Co., Ltd. (JP) 2004-05-06 EP disclosed
CN-1468215-A 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation ����ҩƷ��ҵ��ʽ���� 2004-01-14 CN disclosed
EP-1331221-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION Kissei Pharmaceutical Co., Ltd. (JP) 2003-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205812-A1 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation F12, F2, F5 CA2 1040/4885CA1 3337/4885CA9 883/4885
US-20050014787-A1 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof F2, HYPK, F10 CA2 1021/4885CA1 288/4885CA9 383/4885
US-20040242455-A1 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor F11, F2, F7 CA2 1903/4885CA1 3513/4885CA9 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.